A carregar...
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
BACKGROUND: During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels. PCSK9 is secreted by the liver into the plasma and binds the hepatic LDL receptor, causing its subsequent degradation. In humans,...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3055818/ https://ncbi.nlm.nih.gov/pubmed/21352602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-511X-10-38 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|